In the Claims:

Claims 1 to **34** (cancelled).

Claim 35 (currently amended) A compound of the formula



$(I)_G$

in racemic, enantiomeric form or any combination of these forms, in which Het is a heterocycle with 5 members ~~comprising~~ consisting of 2 heteroatoms and such that formula $(I)_G$ ~~corresponds exclusively to one of the following sub-formulae~~ is:



$(I)_{G1}$

; or



$(I)_{G2}$,

in which

A is



~~radical~~ in which Q is $-OR^{22}$ and R^{22} is hydrogen

and R^{19}, R^{20} and R^{21} are hydrogen or alkyl or alkyl,

X is –S-,

R^1 and R^2 are hydrogen,

B is hydrogen,

Ω is $NR^{46}R^{47}$,

R^{46} and R^{47} are hydrogen ~~or alkyl~~;

n, each time that they occur, is independently an integer from 0 to 6;

and its pharmaceutically acceptable salts.

Cancel **Claim 36**.

Claim 37 (previously presented) The compound of claim 35 or its salt, wherein n is an integer from 0 to 2.

Claim 38 (currently amended) The compound of claim 37 or its salt, wherein ~~n is 1~~ R_1 and R_2 are hydrogen.

Claim 39 (currently amended) The compound of claim 37 or its salt, wherein ~~n is 1 0~~ R_1 is hydrogen and R_2 is alkyl.

Claim 41 (currently amended) A pharmaceutical composition ~~containing,~~ comprising ~~as active principle,~~ a compound of ~~general formula (I)$_G$ as defined in~~ claim 35, ~~or a pharmaceutically acceptable compound of such a compound,~~ and at least one pharmaceutically acceptable excipient.

Cancel **Claim 42**.

Claim 43 (currently amended) The pharmaceutical composition of claim ~~18~~ 41 wherein the active principle is butyl 2-(4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl) ethylcarbamate or one of its pharmaceutically acceptable salts.

Claim 44 (cancelled).

Cancel **Claims 45** to **48**.

Add the following claim:

Claim 49 (new) A compound of claim 35 wherein n is 0.